Mesoblast Limited (MESO)
NASDAQ: MESO · Real-Time Price · USD
17.30
+0.63 (3.78%)
Jan 17, 2025, 4:00 PM EST - Market closed
Mesoblast Employees
Mesoblast had 73 employees as of June 30, 2024. The number of employees decreased by 10 or -12.05% compared to the previous year.
Employees
73
Change (1Y)
-10
Growth (1Y)
-12.05%
Revenue / Employee
$80,849
Profits / Employee
-$1,204,877
Market Cap
2.20B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
MESO News
- 10 days ago - Top 2 Health Care Stocks That Are Ticking Portfolio Bombs - Benzinga
- 4 weeks ago - Mesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges - Benzinga
- 4 weeks ago - Mesoblast's RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy - GlobeNewsWire
- 4 weeks ago - US FDA approves Mesoblast's cell therapy for graft-versus-host disease - Reuters
- 4 weeks ago - Mesoblast to be Added to Nasdaq Biotechnology Index - GlobeNewsWire
- 5 weeks ago - RFK Jr. could prove a surprise boon for stem-cell stocks with pivotal year ahead - Market Watch
- 6 weeks ago - FDA Grants Revascor® (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart Disease - GlobeNewsWire
- 7 weeks ago - Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation - GlobeNewsWire